[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patients-reported-outcomes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patients-reported-outcomes":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100636817","development-and-validation-of-a-chinese-quality-of-life-scale-for-pulmonary-arterial-hypertension-100636817",false,"NCT07570615","Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension","Development and Validation of a Chinese Patient-Reported Outcome Measure for Quality of Life in Pulmonary Arterial Hypertension Patients","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed with pulmonary arterial hypertension\n* Able to read and complete questionnaires\n* Provided informed consent\n\nExclusion Criteria:\n\n* Severe physical condition preventing participation\n* History of psychiatric disorders or current use of psychiatric medication\n* Pregnancy or lactation\n* Any condition preventing completion of questionnaires","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in China.\n\nThe study includes two phases: (1) scale development using literature review, Delphi expert consultation, and patient interviews; and (2) multicenter prospective observational validation to evaluate reliability, validity, and responsiveness.\n\nThe final scale is expected to support clinical assessment, treatment monitoring, and health policy decision-making.",[24,25,26],"Pulmonary Arterial Hypertension (PAH)","Quality of Life","Patients Reported Outcomes","NOT_YET_RECRUITING","2026-04-30",{"date":30,"type":31},"2026-05-06","ACTUAL",{"date":28,"type":20},{"date":34,"type":20},"2029-04-30",{"name":36,"class":37},"Chinese Pulmonary Vascular Disease Research Group","OTHER"]